PMID- 27775780
OWN - NLM
STAT- MEDLINE
DCOM- 20170804
LR  - 20180318
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 20
IP  - 19
DP  - 2016 Oct
TI  - A novel lecithin based delivery form of Boswellic acids (Casperome(R)) for the 
      management of osteo-muscular pain: a registry study in young rugby players.
PG  - 4156-4161
LID - 11541 [pii]
AB  - OBJECTIVE: Several experimental studies and clinical trials support the potential 
      of Boswellia serrata extracts (BSE) for the treatment of various inflammatory 
      diseases. The aim of this registry study was to assess the safety and the 
      efficacy of a novel lecithin-based delivery form of Boswellia serrata extract 
      (Casperome(R)) in the supportive management of osteo-muscular pain. PATIENTS AND 
      METHODS: 52 healthy young rugby players with acute knee pain and inflammation 
      were recruited. Informed participants freely decided to follow either a standard 
      management (SM) to control joint pain (control group = 27) or SM associated with 
      oral daily supplementation with Casperome(R) (supplement group =25). Parameters 
      associated with osteo-muscular pain and inflammation, and measurements of joint 
      health and functions were assessed at the inclusion and after a 4-week 
      supplementation. RESULTS: A significant beneficial effect of Casperome(R) vs SM 
      alone was observed for all the parameters evaluated, namely: local pain on 
      effort; pain-free walking distance (treadmill test); minimal joint effusion; 
      structural damage (joint, tendons, muscles) and intramuscular hematomas; thermal 
      imaging of the anterior knee; Visual Analog Scale for Pain (VAS Pain); need for 
      concomitant drugs and medical attention; measurement of inflammatory biomarkers. 
      CONCLUSIONS: Our registry study suggests that Casperome(R) supplementation could 
      represent an effective and safe, integrated approach for the treatment of 
      osteo-muscular pain and inflammation.
FAU - Franceschi, F
AU  - Franceschi F
AD  - Indena SpA, Milan, Italy. cardres@abol.it.
FAU - Togni, S
AU  - Togni S
FAU - Belcaro, G
AU  - Belcaro G
FAU - Dugall, M
AU  - Dugall M
FAU - Luzzi, R
AU  - Luzzi R
FAU - Ledda, A
AU  - Ledda A
FAU - Pellegrini, L
AU  - Pellegrini L
FAU - Eggenhoffner, R
AU  - Eggenhoffner R
FAU - Giacomelli, L
AU  - Giacomelli L
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Lecithins)
RN  - 0 (Plant Extracts)
RN  - 0 (Triterpenes)
RN  - 631-69-6 (boswellic acid)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Boswellia/*chemistry
MH  - *Football
MH  - Humans
MH  - Knee
MH  - *Lecithins
MH  - Male
MH  - *Pain Management
MH  - Plant Extracts/administration & dosage
MH  - *Registries
MH  - Triterpenes/*therapeutic use
MH  - Young Adult
EDAT- 2016/10/25 06:00
MHDA- 2017/08/05 06:00
CRDT- 2016/10/25 06:00
PHST- 2016/10/25 06:00 [pubmed]
PHST- 2017/08/05 06:00 [medline]
PHST- 2016/10/25 06:00 [entrez]
AID - 11541 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2016 Oct;20(19):4156-4161.